Biologics-Induced Immunophenotypic Cross-Switching in Patients with Psoriasis and Atopic Dermatitis
Indian Journal of Dermatology · 2023-03 · 68 (2) · 186-191
DOI: 10.4103/ijd.ijd_871_22 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Journal of Dermatology, 2023-03. Verfasst von Yanyan Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: From the Shandong Provincial Hospital for Skin Diseases and Shandong Provincial Institute of Dermatology and Venereology, Jinan, Shandong, China. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Antibody-based therapies that inhibit pro-inflammatory cytokine signalling are commonly used in dermatology. Paradoxically, these biological agents may induce or exacerbate paradoxical reactions. Recently, it has been reported that the treatment of eczema with dupilumab can lead to the development of psoriasiform eruptions, which we called psoriasiform paradoxical reactions (P-PRs). Conversely, cases of eczematous paradoxical reactions (E-PRs) have also been described in patients with psoriasis treated with biologics. To summarise the case characteristics and disease features of phenotypic transition between psoriasis and eczematoid dermatitis, and to explore the mechanism or connection related to biological agents or patients’ genetic characteristics, a systematic review was conducted for P-PRs in atopic dermatitis and E-PRs in patients with psoriasis treated with corresponding biological agents, respectively. We identified a series of P-PRs in 42 atopic dermatitis cases treated with dupilumab. The time to onset of P-PRs typically ranged from weeks to months, with a mean latency period of 22.65 weeks. Almost all patients presented with new-onset P-PRs. Simultaneously, we reviewed 22 articles reporting 51 patients with psoriasis with biological agent-induced E-PRs, which occurred on average at 24.47 weeks, 72.55% of them induced by IL-17A inhibitors. 48.98% (24/49) of cases reported a positive personal history of atopy, which may suggest an increased risk of biological agent-induced paradoxical eruptions. Overall, the improvement or resolution upon discontinuation of the inciting biologics was relatively common, and further studies are needed to estimate the real prevalence and unveil the pathophysiological mechanisms of these paradoxical events.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- From the Shandong Provincial Hospital for Skin Diseases and Shandong Provincial Institute of Dermatology and Venereology, Jinan, Shandong, China.
- Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Zitieren
APA
Li, Y., Liu, H., & Zhang, F. (2023). Biologics-Induced Immunophenotypic Cross-Switching in Patients with Psoriasis and Atopic Dermatitis. Indian Journal of Dermatology, 68(2), 186-191. https://doi.org/10.4103/ijd.ijd_871_22
Vancouver
Li Y, Liu H, Zhang F. Biologics-Induced Immunophenotypic Cross-Switching in Patients with Psoriasis and Atopic Dermatitis. Indian Journal of Dermatology. 2023;68(2):186-191. doi:10.4103/ijd.ijd_871_22
BibTeX
@article{Li2023,
author = {Li, Yanyan and Liu, Hong and Zhang, Furen},
title = {Biologics-Induced Immunophenotypic Cross-Switching in Patients with Psoriasis and Atopic Dermatitis},
journal = {Indian Journal of Dermatology},
year = {2023},
volume = {68},
number = {2},
pages = {186--191},
doi = {10.4103/ijd.ijd_871_22}
}
EUVIMED